Acrivon Confirms 52% Response Rate in Serous EC, Sustaining Efficacy Amid Skepticism

What happened

Acrivon Therapeutics reported Q4 and full-year 2025 financial results, with maturing data from the Phase 2b ACR-368 study showing a confirmed overall response rate of 52% in serous endometrial cancer, unchanged from the January 2026 update. This follows the ESGO presentation in late February 2026, a key credibility catalyst highlighted in the DeepValue report, which aimed to address durability concerns. The sustained cORR suggests the efficacy signal is holding as more data accumulates, reinforcing the serous subtype focus critical to the registrational path. However, the data remains interim and subject to verification risks per SEC filings, with the market still awaiting proof of enrollment throughput and durability details. The report does not alter the near-term milestones, including EU enrollment initiation by March 31, 2026, and a mid-2026 data update, which are essential for de-risking the stock.

Implication

First, the sustained response rate reduces immediate downside from data deterioration, aligning with the DeepValue base scenario of ≥45% cORR. Second, it validates the serous subtype strategy and may aid regulatory discussions for Phase 3 planning. Third, with $134.4M cash runway into Q2 2027, the company has buffer to execute without near-term financing pressure. Fourth, however, skepticism persists as the market needs evidence of Arm 3 EU enrollment start by end-March and mid-2026 data with follow-up details to assess durability. Fifth, thus, while positive, this news alone does not shift the investment call, emphasizing that stock repricing hinges on operational execution and data transparency in the next 3-6 months.

Thesis delta

The new article confirms ACR-368's cORR remains at 52%, reinforcing the efficacy signal without deterioration, which slightly boosts confidence in the serous pocket thesis. However, no material shift occurs as critical catalysts—EU enrollment initiation by March 31 and mid-2026 data with durability context—are still pending and essential for proving registrational viability. The thesis remains a 'POTENTIAL BUY' with conviction dependent on these near-term milestones, as outlined in the DeepValue report.